Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chinese biotechnology company Sinobiopharma has secured rights to seven key patents from company CEO Lequn Huang and the patents' co-holders.
Subscribe to our email newsletter
Sinobiopharma has acquired rights to the following patents – Synthesis of amantadine hydrochloride, method for preparation of 17-acylsinomenine derivatives, preparation of 17-sulfonylsinomenine, preparation of N-substituted sinomenine, method for preparation of Sinomenine compound having dextro-rotary C ring-deficient morphinan skeleton, synthesis of Eplerenone from 11 -hydroxycanrenone and method for resolving tetrahydroisoquinoline racemate.
The patents are expected to significantly enhance Sinobiopharma’s ability to execute on its mission of bringing safe, low-cost, high-efficacy biopharmaceuticals to market.
Sinobiopharma will be applying these patents as well as using its own innovative applications of them in new drug development.